CLINICAL TRIALS PROFILE FOR GEMCITABINE HYDROCHLORIDE

505(b)(2) Clinical Trials for GEMCITABINE HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00003589 ↗	Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1998-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating advanced non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of three different combination chemotherapy regimens in treating patients who have advanced non-small cell lung cancer.
New Combination	NCT01050322 ↗	Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.	Completed	GlaxoSmithKline	Phase 2	2009-11-01	Despite these initial positive signals in recent statistics, breast cancer continues to claim a substantial number of lives approximately 500,000 deaths worldwide in 2005 Thus the current treatment paradigm - surgery, radiation and systemic chemo and or hormonal therapy and biological therapies -still fails to cure a significant number of women with early breast cancer and new treatment strategies are needed to improve current results both in early and advance disease. Recurrent or metastatic breast cancer is an incurable malignancy with a median survival of 20-24 months [Hortobagyi , 1998] and this has not changed significantly over the last decade with fewer than 20% of patients still alive at 5 years after a diagnosis of recurrence. Although there have been small improvements in survival with the new therapies, metastatic breast cancer remains an incurable and, ultimately, fatal disease. The introduction of novel combination therapies have the potential to target different pathways in the cancer cell, leading to improved efficacy. Further studies to optimize combination therapy, while ameliorating AEs, are critically important to patients with metastatic breast cancer. Lapatinib is an oral tyrosine kinase inhibitor which potently inhibits both EGFR and HER2[Spector, 2005]. Lapatinib in combination with capecitabine is approved in more than 20 countries for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2. All patients in the study leading to the lapatinib approval had received prior therapy including an anthracycline, a taxane, and trastuzumab. The relevance of the HER2/neu target in breast cancer, combined with the promising preclinical and clinical data regarding the use of lapatinib, provide the rationale for a formal evaluation of this agent combined with other non taxane agents as gemcitabine or vinorelbine after progression on taxanes and trastuzumab based therapies in metastatic disease setting as these chemotherapy options are used in daily practice in this subset of patients. This is a randomized phase II, open label,multicentric , international, 3 arms treatment study in patients with confirmed HER2+ metastatic breast cancer after taxane progression . The main objective is to investigate the (CBR) and safety in 3 different combinations of Lapatinib therapy (plus capecitabine or gemcitabine or vinorelbine) and to determine whether either, or both, of Lapatinib /Vinorelbine or Lapatinib/Gemcitabine can be considered a reasonable alternative to the established Lapatinib/Capecitabine standard combination . The decision as to whether to study either of the new combinations further will be based on both the toxicity and the efficacy profiles.
New Combination	NCT01050322 ↗	Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.	Completed	Latin American Cooperative Oncology Group	Phase 2	2009-11-01	Despite these initial positive signals in recent statistics, breast cancer continues to claim a substantial number of lives approximately 500,000 deaths worldwide in 2005 Thus the current treatment paradigm - surgery, radiation and systemic chemo and or hormonal therapy and biological therapies -still fails to cure a significant number of women with early breast cancer and new treatment strategies are needed to improve current results both in early and advance disease. Recurrent or metastatic breast cancer is an incurable malignancy with a median survival of 20-24 months [Hortobagyi , 1998] and this has not changed significantly over the last decade with fewer than 20% of patients still alive at 5 years after a diagnosis of recurrence. Although there have been small improvements in survival with the new therapies, metastatic breast cancer remains an incurable and, ultimately, fatal disease. The introduction of novel combination therapies have the potential to target different pathways in the cancer cell, leading to improved efficacy. Further studies to optimize combination therapy, while ameliorating AEs, are critically important to patients with metastatic breast cancer. Lapatinib is an oral tyrosine kinase inhibitor which potently inhibits both EGFR and HER2[Spector, 2005]. Lapatinib in combination with capecitabine is approved in more than 20 countries for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2. All patients in the study leading to the lapatinib approval had received prior therapy including an anthracycline, a taxane, and trastuzumab. The relevance of the HER2/neu target in breast cancer, combined with the promising preclinical and clinical data regarding the use of lapatinib, provide the rationale for a formal evaluation of this agent combined with other non taxane agents as gemcitabine or vinorelbine after progression on taxanes and trastuzumab based therapies in metastatic disease setting as these chemotherapy options are used in daily practice in this subset of patients. This is a randomized phase II, open label,multicentric , international, 3 arms treatment study in patients with confirmed HER2+ metastatic breast cancer after taxane progression . The main objective is to investigate the (CBR) and safety in 3 different combinations of Lapatinib therapy (plus capecitabine or gemcitabine or vinorelbine) and to determine whether either, or both, of Lapatinib /Vinorelbine or Lapatinib/Gemcitabine can be considered a reasonable alternative to the established Lapatinib/Capecitabine standard combination . The decision as to whether to study either of the new combinations further will be based on both the toxicity and the efficacy profiles.
New Combination	NCT01270724 ↗	Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)	Completed	Nationwide Children's Hospital	Phase 2	2010-08-01	This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.

All Clinical Trials for GEMCITABINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001431 ↗	A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas	Completed	National Cancer Institute (NCI)	Phase 1	1995-02-01	Radiotherapy plus Single-Agent Chemotherapy/Radiosensitization. Involved-field irradiation using 4-15 MV photons; plus Gemcitabine, NSC-613327.
NCT00001449 ↗	A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients	Completed	National Cancer Institute (NCI)	Phase 1	1995-09-01	The purpose of this study is to determine the clinical toxicities associated with administering sequential dFdC as a one hour infusion followed by a continuous infusion of FUdR over 24 hours with low dose oral LV weekly for three weeks out of four.
NCT00002998 ↗	Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine and cisplatin in treating patients with metastatic breast cancer that has not responded to systemic therapy.
NCT00002998 ↗	Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer	Completed	Alliance for Clinical Trials in Oncology	Phase 2	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine and cisplatin in treating patients with metastatic breast cancer that has not responded to systemic therapy.

Clinical Trial Conditions for GEMCITABINE HYDROCHLORIDE

Condition Name

Condition Name for GEMCITABINE HYDROCHLORIDE
Intervention	Trials
Pancreatic Cancer	456
Breast Cancer	111
Lung Cancer	107
Bladder Cancer	107

Condition MeSH

Condition MeSH for GEMCITABINE HYDROCHLORIDE
Intervention	Trials
Pancreatic Neoplasms	869
Carcinoma, Non-Small-Cell Lung	384
Adenocarcinoma	364
Lung Neoplasms	361

Clinical Trial Locations for GEMCITABINE HYDROCHLORIDE

Trials by Country

Trials by Country for GEMCITABINE HYDROCHLORIDE
Location	Trials
Greece	97
Argentina	95
Switzerland	94
Mexico	93
Austria	91

Trials by US State

Trials by US State for GEMCITABINE HYDROCHLORIDE
Location	Trials
California	502
New York	485
Texas	466
Florida	394
Pennsylvania	390

Clinical Trial Progress for GEMCITABINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for GEMCITABINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	78
PHASE2	201

Clinical Trial Status

Clinical Trial Status for GEMCITABINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	1205
Recruiting	651
Terminated	320

Clinical Trial Sponsors for GEMCITABINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for GEMCITABINE HYDROCHLORIDE
Sponsor	Trials
National Cancer Institute (NCI)	441
Eli Lilly and Company	185
Sun Yat-sen University	75

Sponsor Type

Sponsor Type for GEMCITABINE HYDROCHLORIDE
Sponsor	Trials
Other	3337
Industry	1698
NIH	455

Gemcitabine Hydrochloride Clinical Trials Update, Market Analysis, and Forecast (2026-2035)

Last updated: July 25, 2026

Gemcitabine hydrochloride is an established cytotoxic nucleoside analog used across multiple oncology settings. The clinical-trial pipeline in 2024-2026 is dominated by combinations (chemo-doublets and chemo-immunotherapy), new delivery approaches (including tumor-activated prodrugs and formulation work where disclosed), and rare-species and regimen-adaptation studies rather than a single “next-generation” monotherapy readout. Market growth is constrained by maturity, generic availability in most geographies, and ongoing pricing pressure, with upside coming from combination uptake, line-of-therapy expansion in specific tumor types, and higher utilization in hepatobiliary and lung cancers.

What clinical trials are ongoing for gemcitabine hydrochloride in 2024-2026?

Answer: Ongoing activity clusters around (1) gemcitabine-containing combinations in pancreatic, biliary tract, and non-small cell lung cancer (NSCLC), (2) immunotherapy pairing in urothelial carcinoma and NSCLC, and (3) regimen and population refinements. Trial reporting and design patterns in this period show a shift toward biomarker-stratified cohorts, earlier use in selected combinations, and sequence optimization rather than stand-alone monotherapy trials.

Pancreatic ductal adenocarcinoma (PDAC)

Trial themes

• Gemcitabine-based doublets continued in first-line and neoadjuvant-adjacent strategies, including combinations with platinum agents and targeted biologics where eligibility permits.
• Trials frequently evaluate gemcitabine plus immune checkpoint inhibitors or gemcitabine plus other systemic agents, with endpoints focused on OS, PFS, and response durability.

Key execution pattern

• Randomized or phase 2/3 platform-style studies with early response biomarkers and enrichment based on molecular profiling.

Biliary tract cancers

Trial themes

• Gemcitabine-centered regimens are tested in combination settings due to historically favorable activity signals with gemcitabine backbone therapies.
• Studies track OS and safety with attention to hepatic function and dose-modification algorithms.

NSCLC

Trial themes

• Gemcitabine combinations are evaluated in NSCLC, often where prior lines or specific molecular subsets drive use.
• Trials include chemo-immunotherapy and chemo-targeted combinations, with stratification by PD-L1 status and histology.

Urothelial carcinoma

Trial themes

• Gemcitabine-based chemo-immunotherapy trials continue in muscle-invasive disease-adjacent pathways and metastatic settings, with attention to tolerability and dosing consistency.

What were the most important gemcitabine hydrochloride clinical readouts in the past 24 months?

Answer: The most actionable readouts are combination-dependent: improved outcomes in selected subgroups or regimen sequencing, with no broad displacement of gemcitabine backbone standards. The dominant pattern is incremental benefit rather than a single decisive “replacement” regimen across tumor types.

Readout types that matter commercially

• OS and PFS improvements in predefined biomarker strata
• Reduced toxicity or improved dose intensity via regimen tailoring
• Confirmed feasibility of combination sequencing (gemcitabine with immunotherapy and targeted agents)

Commercial interpretation

• Uptake is expected where a gemcitabine-containing regimen becomes preferred first-line or second-line standard-of-care in a segment.
• Where trials show no net benefit or narrow benefit, penetration tends to remain behind best-in-class alternatives and is more sensitive to pricing and access than to clinical differentiation.

How big is the gemcitabine hydrochloride market and where does revenue come from?

Answer: Revenue is generated primarily by use in pancreatic cancer, biliary tract cancers, and NSCLC across multiple lines of therapy. Because gemcitabine is widely genericized, market value is more a function of unit volumes, tendering dynamics, and regional pricing than patent-driven premium economics.

Market structure

• Supply: Multi-generic competition in many jurisdictions; branded supply is limited by time-to-generic and local approvals.
• Demand drivers: Incidence of relevant cancers, persistence of gemcitabine as a backbone regimen, and combination adoption.
• Pricing pressure: Ongoing, with periodic stabilization after supply disruptions and tender cycles.

Revenue pool by therapeutic area (directional)

• Largest: PDAC (high regimen intensity and sustained use).
• Material: biliary tract cancers (gemcitabine backbone is standard in multiple settings).
• Material: NSCLC (combinations in specific populations, often later lines depending on region).
• Smaller contributions: urothelial carcinoma and other solid tumors with gemcitabine-based regimens.

What is the gemcitabine market forecast for 2026-2035?

Answer: Total market growth is expected to be moderate and driven by volume and combination mix, with limited headroom from pricing. Growth rates should track global cancer burden trends and uptake of combination regimens rather than any patent-protected premium.

Base-case projection logic

• Volume: grows with incidence and treatment rates.
• Mix: modest shift toward earlier lines and specific tumor subtypes where gemcitabine combinations show incremental benefit.
• Price: continues to compress in generic-heavy markets, offset by periodic supply-side volatility.

Forecast scenarios (directional, not brand-level)

• Base case: low-to-mid single digit CAGR globally, with regional variation.
• Upside: stronger chemo-immunotherapy adoption and improved sequencing results in PDAC and biliary tract cancers.
• Downside: faster replacement by non-gemcitabine regimens in frontline PDAC in some geographies, or intensified price compression from additional generic entrants.

Does gemcitabine hydrochloride have active patent protection that affects generic competition?

Answer: For many markets, gemcitabine hydrochloride as an active ingredient is off patent. Competitive access is determined less by core substance patents and more by (1) specific branded product patents in certain jurisdictions, (2) formulation or manufacturing-process patents (where asserted), and (3) any country-specific secondary protections, if still in-force.

What typically constrains generics for gemcitabine

• Process patents (manufacturing controls)
• Finished-dose formulation patents (where applicable in select jurisdictions)
• Labeling or method-of-use protections (limited utility because of broad standard-of-care use and generic label parity)

Litigation and Paragraph IV risk framing

Gemcitabine’s genericization risk is generally high because ANDA entrants do not need to “solve” the core API protection. If any secondary patents remain, the relevant risk is whether ANDA filers must carve out protected indications, dosage forms, or manufacturing steps.

What is the Orange Book status of gemcitabine hydrochloride products in the US?

Answer: Gemcitabine hydrochloride products are broadly represented by multiple abbreviated new drug applications (ANDAs) and are typically listed with a mix of patent information (some expired, some expired or tied to specific formulations). In practice, the Orange Book listings reflect generic availability rather than exclusivity-led market protection.

Practical regulatory implication

• FDA access depends on ANDA approval status, launch timing, labeling, and any listed patents that could trigger litigation.
• For market projection, the key variable is not exclusivity but competitive intensity at the wholesale and tender levels.

How do gemcitabine hydrochloride clinical outcomes compare with alternative regimens?

Answer: Gemcitabine remains a key backbone because it combines efficacy with an established safety and administration profile. Its competitive position differs by tumor type and by the “standard of care” comparator in each line. In some PDAC and biliary tract settings, gemcitabine-containing regimens remain entrenched; in other settings, newer regimens may reduce share of gemcitabine-only use.

Comparison factors that influence switching

• OS/PFS benefit vs comparator regimens
• Toxicity and tolerability allowing continuation
• Compatibility with immunotherapy and targeted agents
• Practical dosing schedules and resource utilization

Which companies are supplying gemcitabine hydrochloride, and how does competition affect price?

Answer: Competition is driven by multiple generic manufacturers across the US, Europe, India, and China supply chains, with pricing influenced by tender systems, regulatory approvals, and procurement contracts. Market share tends to rotate based on availability and cost rather than differentiation.

Competitive dynamics that matter for forecasting

• Short-term: supply constraints causing price spikes and temporary volume shifts.
• Medium-term: more entrants compress price further.
• Structural: contracting favors lowest-cost reliable supply.

What formulation innovations exist for gemcitabine hydrochloride and do they change commercial outlook?

Answer: Innovation is mostly incremental and combination/administration oriented in publicly disclosed development. Where new delivery or prodrug concepts exist, commercialization impact depends on whether they demonstrate clear clinical advantage and regulatory approval in defined indications.

What would change the forecast materially

• A clearly superior, regulator-approved formulation that improves survival or reduces toxicity meaningfully across a broad segment.
• Strong uptake in first-line regimens that displaces existing gemcitabine products.

What generic entry risks exist for gemcitabine hydrochloride in key markets?

Answer: Generic entry risk is high for any remaining protected product presentations, but low for the core API where broad genericization already occurred. The risk profile is driven by any still-active secondary patents and by country-specific regulatory approvals.

Litigation/settlement profile (typical pattern)

• Many cases settle quickly once patent or carve-out issues are addressed.
• Commercial impact tends to be measured in short-term market disruption and reallocation among suppliers.

Regulatory and reimbursement factors: what determines gemcitabine uptake?

Answer: Uptake depends on formulary position and reimbursement status, plus guideline endorsement for gemcitabine-containing regimens. In most markets, gemcitabine is already established and reimbursed, so the main determinants are hospital purchasing contracts and clinical pathway adoption rather than regulatory novelty.

Use constraints

• Dose modifications in renal/hepatic impairment
• Scheduling fit with infusion capacity
• Patient selection and sequencing with immunotherapies

Key pipeline and market “watch items” for 2026

Answer: The highest-signal items are not monotherapy expansions but combination readouts with clear outcome differentiation and biomarker-enriched survival benefits.

Watch list categories

• PDAC phase 2/3 combination outcomes that show OS differentiation vs standard gemcitabine doublets
• Biliary tract trial outcomes confirming gemcitabine backbone superiority in defined subgroups
• NSCLC studies that define where gemcitabine-based therapy regains share vs non-gemcitabine standards
• Any approved formulation or delivery improvement that changes toxicity profile enough to shift guideline preference

---

Key Takeaways

• Gemcitabine hydrochloride demand remains anchored by PDAC and biliary tract cancers as a backbone therapy, with additional use in NSCLC and urothelial carcinoma combinations.
• Clinical development in 2024-2026 is combination-led and sequence-optimized, with incremental benefits and biomarker stratification rather than broad monotherapy displacement.
• Market growth is likely moderate through 2035, driven by volume and mix, offset by sustained generic pricing pressure.
• Patent-driven premium economics are limited; competitive intensity and procurement dynamics are the main levers for revenue projection.
• The biggest forecast swing factors are outcome-confirming combination trials that change standard-of-care placement and any formulation that materially alters toxicity or efficacy.

FAQs

1. Is gemcitabine hydrochloride still used in first-line pancreatic cancer in 2026?
2. Do gemcitabine-based combinations improve outcomes when paired with immune checkpoint inhibitors in NSCLC?
3. What dosing schedules for gemcitabine most affect tolerability and continuation rates?
4. How does hospital tendering influence regional gemcitabine pricing and supplier switching?
5. Are there any still-protected gemcitabine formulations in the US that delay generic entry?

References

1. APA: FDA. “Drugs@FDA: FDA Approved Drug Products.” U.S. Food and Drug Administration.
2. APA: FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
3. APA: ClinicalTrials.gov. “Gemcitabine hydrochloride (Search).” U.S. National Library of Medicine.